Fig. 4.

Neutralization of IL-17A abolishes the worse outcome of Il10^−/− mice. Triphenyltetrazolium chloride staining was used for evaluation of infarct volume at day 7 of IL-17A antibody (A) or IgG control (C) treated Il10^−/− and WT control mice. Bederson score was performed 7 days after tMCAO IL-17A antibody (B) or in IgG control (D) treated group. Infarct data are presented as mean ± SEM of 9–11 WT and 6–9 Il10^−/− mice per group. Bederson score as mean ± SEM of 9–11 WT and 7–10 Il10^−/− mice per group. Statistical significances were analyzed by Student t test (A, C) and Mann–Whitney U test (B, D). *P < 0.05